search
Back to results

Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.

Primary Purpose

Rotavirus Infections, Rotavirus Vaccines

Status
Completed
Phase
Phase 3
Locations
Russian Federation
Study Type
Interventional
Intervention
The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)
Placebo
Sponsored by
Limited Liability Company Pharm Aid
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Rotavirus Infections

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. The signed informed consent;
  2. Healthy participants, men's and females aged from 18 up to 45 years inclusive;
  3. Readiness of participants and their sexual partners to use reliable methods of contraception (a combination of at least two modes, including one barrier method, for example, use of a spermicide and condom) from the moment of signing of the informed consent (that is in 3 days before administration of drugs) and before the expiration of 1 month after completion of participation in the study;
  4. The verified diagnosis "is healthy," established according to collecting the anamnesis and physical inspection:

    • absence in the anamnesis and at the time of screening clinically significant dysfunctions cardiovascular, respiratory, nervous, hemopoietic, endocrine, gastrointestinal systems, liver, and kidneys;
    • absence of persistent infections (HIV, hepatitis B, C, syphilis);
    • absence within 30 days before inclusion in the study of sharp, infectious diseases;
    • absence of the mental disorders and any other states capable to affectability of the participant to follow requirements of the protocol;
    • lack of complaints to the state of health within 30 days before inclusion in the study;
    • hemodynamic indicators within norm: systolic arterial blood pressure - within 100 - 130 mm Hg., diastolic arterial blood pressure - within 60 - 90 mm Hg;
  5. The Body Mass Index (BMI) is in normal limits (≥18.5 kg/sq.m and ≤30 kg/sq.m);
  6. There is a lack of instructions on alcohol abuse or narcotic dependence at the time of inclusion in study or the anamnesis;
  7. The participant's Ability, according to the study, to fulfill the requirements of the protocol.

Exclusion Criteria:

  1. The severe vaccine-challenged reactions/complications connected with the previous vaccination;
  2. Allergic reactions to components of vaccine or any previous vaccination;
  3. Any carried-out vaccination less than in 2 months before the present study;
  4. In the chronic anamnesis diseases of the digestive tract, causes intestinal invagination, gastrointestinal pathology, surgical interventions on abdominal organs;
  5. Clinically significant deviations of laboratory and tool indicators (including standard pathological changes on the ECG) overstepping the bounds of the range of normal values revealed on screening and capable of negatively impacting the safety of participants of the volunteer in the study;
  6. Any diseases within four weeks preceding screening;
  7. Presence of any oncological diseases (including in the anamnesis);
  8. Any disease demands continuous therapy, including vegetable drugs or the expected concurrent therapy during the study;
  9. Donor blood donation (450 ml of blood or plasma and more) or loss of 500 or more ml of blood in 3 months before the study;
  10. Positive analysis on HIV, Hepatitis B and C, and syphilis (RW);
  11. Impossibility to give the written informed consent or to follow requirements of the protocol;
  12. Probability to refuse to follow the protocol's requirements, instructions and restrictions; for example, unwillingness to cooperate, impossibility to return to clinical center for the subsequent visits, and the probability not of completion of participation in a clinical trial;
  13. Participation in clinical trials of drugs less than in 3 months before the study;
  14. Smoking more than ten cigarettes in a day;
  15. Drug addiction in the anamnesis. The positive analysis of urine on psychotropic and narcotic substances, psychoactive medicines;
  16. Regular alcohol intake in many ˃10 units a week (to 1 unit of alcohol is equivalent to ½ l of beer, 200 ml of wine, or 50 ml of hard liquors) or anamnestic data on alcoholism. Alcohol intake within 48 hours before the Screening visit. Positive respiratory test for alcohol on screening (breathalyzer);
  17. Observance of a special diet (for example, vegetarian, observance of a post, etc.) or lifestyle (including work at night and extreme physical activities, such as sport or raising of weights) which can interfere with carrying out the study;
  18. The study cannot include military personnel or employees law enforcement agencies serving sentences in places of detention or being in custody;
  19. The presence of conviction of the study is that the volunteer will not follow procedures of the protocol;
  20. Use of any medicines, including OTC, vegetable medicines, dietary supplements, within 14 days before the study, according to the study.

Sites / Locations

  • Perm State Medical University named after Academician E.A. Wagner

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

The pentavalent rotavirus vaccine - Rota-V-Aid™ (live attenuated oral, freeze-dried)

Diluent is a sterile solution (Citrate Bicarbonate Buffer)

Arm Description

Live attenuated bovine-human [UK] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is lyophilized and supplied with 2.5 ml of citrate bicarbonate buffer added for reconstitution before oral administration.

Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.

Outcomes

Primary Outcome Measures

Geometric Mean Titer (GMT) of antibody
Seroconversion level
Seroconversion factor (The increase in the geometric mean antibody titer on day 28 compared to the initial level is expressed in the fold increase.).
The seroconversion factor after administration of the study vaccine was 1.20, after administration of placebo - 0.97.
Frequency and expressiveness of AE /SAE.

Secondary Outcome Measures

Full Information

First Posted
August 18, 2021
Last Updated
August 31, 2021
Sponsor
Limited Liability Company Pharm Aid
search

1. Study Identification

Unique Protocol Identification Number
NCT05037435
Brief Title
Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.
Official Title
Prospective, Randomized, Double-blind, Placebo-controlled Clinical Study of the Safety and Efficacy of the Vaccine for the Prevention of Pentavalent Live Rotavirus Infection in Healthy Subjects (Target Age of 18-45 Years Old).
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
June 25, 2018 (Actual)
Primary Completion Date
July 27, 2018 (Actual)
Study Completion Date
July 27, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Limited Liability Company Pharm Aid

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the presented study was to evaluate the safety and immunological efficacy in preventing the rotavirus infection within a cohort of healthy subjects (target age of 18-45 years old) by using the pentavalent rotavirus vaccine - Rota-V-Aid™ (live attenuated oral, freeze-dried).
Detailed Description
The clinical study named "Prospective, randomized, double-blind, placebo-controlled study of safety and immunological efficacy for preventing a rotavirus infection pentavalent vaccine, live attenuated at the healthy subjects at the age of 18-45 years" was conducted in the Russian Federation. The mentioned study was performed as per Protocol of clinical trial No. RTB 001/18 (given by MOH RF exp June 7, 2018). All relevant requirements of the National Legislative system and the international rules of conduct of clinical trials (ICH GCP). The study objective was to assess the safety and immunological efficacy for preventing a rotavirus infection pentavalent rotavirus vaccine - Rota-V-Aid™ (live attenuated oral, freeze-dried) at healthy adults aged 18 to 45 years for the subsequent vaccination of the children's contingent. For the achievement of a goal, it was necessary to solve the following problems: Assessment of the vaccine's safety for preventing a rotavirus infection pentavalent live compared to placebo at a single oral introduction to volunteers at the age of 18-45 years. Immunological efficacy assessment for prevention of a rotavirus infection pentavalent live in comparison with placebo at a single oral introduction to volunteers at the age of 18-45 years

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rotavirus Infections, Rotavirus Vaccines

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Prospective randomized double-blind placebo-controllable.
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
The pentavalent rotavirus vaccine - Rota-V-Aid™ (live attenuated oral, freeze-dried)
Arm Type
Experimental
Arm Description
Live attenuated bovine-human [UK] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is lyophilized and supplied with 2.5 ml of citrate bicarbonate buffer added for reconstitution before oral administration.
Arm Title
Diluent is a sterile solution (Citrate Bicarbonate Buffer)
Arm Type
Placebo Comparator
Arm Description
Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
Intervention Type
Biological
Intervention Name(s)
The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)
Other Intervention Name(s)
Rota-V-Aid™
Intervention Description
Group 1 (20 participants) - received the pentavalent live vaccine to prevent rotavirus infection Single-use orally 2.5 ml (1 dose).
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
Diluent is a sterile solution (Citrate Bicarbonate Buffer)
Intervention Description
Group 2 (20 participants ) - received placebo orally once of 2.5 ml (1 dose).
Primary Outcome Measure Information:
Title
Geometric Mean Titer (GMT) of antibody
Time Frame
28 days post-Dose 1
Title
Seroconversion level
Time Frame
28 days after Dose 1 of vaccine
Title
Seroconversion factor (The increase in the geometric mean antibody titer on day 28 compared to the initial level is expressed in the fold increase.).
Description
The seroconversion factor after administration of the study vaccine was 1.20, after administration of placebo - 0.97.
Time Frame
28 days post-Dose 1
Title
Frequency and expressiveness of AE /SAE.
Time Frame
From the time of Dose 1 to 28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: The signed informed consent; Healthy participants, men's and females aged from 18 up to 45 years inclusive; Readiness of participants and their sexual partners to use reliable methods of contraception (a combination of at least two modes, including one barrier method, for example, use of a spermicide and condom) from the moment of signing of the informed consent (that is in 3 days before administration of drugs) and before the expiration of 1 month after completion of participation in the study; The verified diagnosis "is healthy," established according to collecting the anamnesis and physical inspection: absence in the anamnesis and at the time of screening clinically significant dysfunctions cardiovascular, respiratory, nervous, hemopoietic, endocrine, gastrointestinal systems, liver, and kidneys; absence of persistent infections (HIV, hepatitis B, C, syphilis); absence within 30 days before inclusion in the study of sharp, infectious diseases; absence of the mental disorders and any other states capable to affectability of the participant to follow requirements of the protocol; lack of complaints to the state of health within 30 days before inclusion in the study; hemodynamic indicators within norm: systolic arterial blood pressure - within 100 - 130 mm Hg., diastolic arterial blood pressure - within 60 - 90 mm Hg; The Body Mass Index (BMI) is in normal limits (≥18.5 kg/sq.m and ≤30 kg/sq.m); There is a lack of instructions on alcohol abuse or narcotic dependence at the time of inclusion in study or the anamnesis; The participant's Ability, according to the study, to fulfill the requirements of the protocol. Exclusion Criteria: The severe vaccine-challenged reactions/complications connected with the previous vaccination; Allergic reactions to components of vaccine or any previous vaccination; Any carried-out vaccination less than in 2 months before the present study; In the chronic anamnesis diseases of the digestive tract, causes intestinal invagination, gastrointestinal pathology, surgical interventions on abdominal organs; Clinically significant deviations of laboratory and tool indicators (including standard pathological changes on the ECG) overstepping the bounds of the range of normal values revealed on screening and capable of negatively impacting the safety of participants of the volunteer in the study; Any diseases within four weeks preceding screening; Presence of any oncological diseases (including in the anamnesis); Any disease demands continuous therapy, including vegetable drugs or the expected concurrent therapy during the study; Donor blood donation (450 ml of blood or plasma and more) or loss of 500 or more ml of blood in 3 months before the study; Positive analysis on HIV, Hepatitis B and C, and syphilis (RW); Impossibility to give the written informed consent or to follow requirements of the protocol; Probability to refuse to follow the protocol's requirements, instructions and restrictions; for example, unwillingness to cooperate, impossibility to return to clinical center for the subsequent visits, and the probability not of completion of participation in a clinical trial; Participation in clinical trials of drugs less than in 3 months before the study; Smoking more than ten cigarettes in a day; Drug addiction in the anamnesis. The positive analysis of urine on psychotropic and narcotic substances, psychoactive medicines; Regular alcohol intake in many ˃10 units a week (to 1 unit of alcohol is equivalent to ½ l of beer, 200 ml of wine, or 50 ml of hard liquors) or anamnestic data on alcoholism. Alcohol intake within 48 hours before the Screening visit. Positive respiratory test for alcohol on screening (breathalyzer); Observance of a special diet (for example, vegetarian, observance of a post, etc.) or lifestyle (including work at night and extreme physical activities, such as sport or raising of weights) which can interfere with carrying out the study; The study cannot include military personnel or employees law enforcement agencies serving sentences in places of detention or being in custody; The presence of conviction of the study is that the volunteer will not follow procedures of the protocol; Use of any medicines, including OTC, vegetable medicines, dietary supplements, within 14 days before the study, according to the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Irina V. Feldblium, Dr. Sci
Organizational Affiliation
Perm State Medical University named after Academician E.A. Wagner
Official's Role
Study Director
Facility Information:
Facility Name
Perm State Medical University named after Academician E.A. Wagner
City
Perm
ZIP/Postal Code
614990
Country
Russian Federation

12. IPD Sharing Statement

Learn more about this trial

Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.

We'll reach out to this number within 24 hrs